Disease characteristics of the SLE clinical trial participants.
| Characteristics | SLE Trial Participants, n = 161 |
|---|---|
| High type I IFNa, n (%) | 121 (75.2) |
| Baseline medication, n (%) | |
| Oral corticosteroids | 115 (71.4) |
| Antimalarials | 111 (68.9) |
| ANA-positive, n (%) | 160 (99.4) |
| SELENA-SLEDAIb, mean (SD) | 11.0 (5.4) |
| BILAG ≥ 1A, n (%) | 39 (24.2) |
| BILAG ≥ 2B no A, n (%) | 76 (47.2) |
| BILAG A, n (%) | |
| General | 2 (1.2) |
| Musculoskeletal | 16 (9.9) |
| Mucocutaneous | 15 (9.3) |
| Renal | 7 (4.3) |
| Hematological | 1 (0.62) |
| BILAG B, n (%) | |
| General | 25 (15.5) |
| Musculoskeletal | 99 (61.5) |
| Mucocutaneous | 90 (55.9) |
| Renal | 12 (7.5) |
| Hematological | 20 (12.4) |
↵a Measured using 4-gene panel of type I IFN-inducible genes.
↵b Patients met at least 1 of 2 criteria for disease activity: SELENA-SLEDAI score ≥ 6 or at least 1 system with a score of A or 2 systems with a score of B on the BILAG index at screening. ANA: antinuclear antibody; BILAG: British Isles Lupus Assessment Group; IFN: interferon; SELENA: Safety of Estrogens in Lupus Erythematosus; SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.